Merging our understanding of immune therapy with cutting-edge discoveries of how the microbiome functions, Rise is developing targeted immunotherapy drugs to treat a broad range of clinical indications.
Synthetic Biology Medicine
As a foundational technology, Rise Therapeutics has developed the innovative and proprietary Tripartite X (TPX) drug delivery platform that embraces synthetic biology-based approaches to enable oral delivery of targeted biologic therapy.
Our clinical GMP drug production capabilities for microbial-based products including Live Biotherapeutic Products (LBPs) enables rapid and efficient translation of innovative bench discoveries towards commercialization.
At Rise Therapeutics, our product development focus, in-house clinical GMP manufacturing capabilities, and drug development experience enables us to pursue rapid and efficient novel drug development from innovative laboratory discoveries.
Interested in working with Us?
Become a Partner
Join Our Team